{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T13:19:21Z","timestamp":1788182361236,"version":"build-2803163510"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":67,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100015811","name":"Science and Technology Department of Ningxia Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015811","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Microbiol"],"DOI":"10.1186\/s12866-026-05240-z","type":"journal-article","created":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T03:54:49Z","timestamp":1781236489000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Characterizing the profile transformation of Helicobacter pylori: increased secondary and multidrug resistance following failed eradication in Ningxia, China"],"prefix":"10.1186","volume":"26","author":[{"given":"Xiaoming","family":"Su","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanxia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaorun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhong","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenfu","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lulu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xilong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengjuan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"issue":"9","key":"5240_CR1","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1136\/gutjnl-2015-309252","volume":"64","author":"K Sugano","year":"2015","unstructured":"Sugano K, Tack J, Kuipers EJ, et al. Kyoto global consensus report on Helicobacter pylori gastritis. Gut. 2015;64(9):1353\u201367. https:\/\/doi.org\/10.1136\/gutjnl-2015-309252.","journal-title":"Gut"},{"issue":"5","key":"5240_CR2","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1136\/gutjnl-2012-302240","volume":"62","author":"YC Lee","year":"2013","unstructured":"Lee YC, Chen TH, Chiu HM, et al. The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention. Gut. 2013;62(5):676\u201382. https:\/\/doi.org\/10.1136\/gutjnl-2012-302240.","journal-title":"Gut"},{"issue":"1","key":"5240_CR3","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1136\/gutjnl-2016-312288","volume":"66","author":"P Malfertheiner","year":"2017","unstructured":"Malfertheiner P, Megraud F, O\u2019Morain CA, et al. Management of Helicobacter pylori infection-the Maastricht V\/Florence Consensus Report. Gut. 2017;66(1):6\u201330. https:\/\/doi.org\/10.1136\/gutjnl-2016-312288.","journal-title":"Gut"},{"issue":"2","key":"5240_CR4","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.cgh.2013.05.028","volume":"12","author":"DY Graham","year":"2014","unstructured":"Graham DY, Lee YC, Wu MS. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence. Clin Gastroenterol Hepatol. 2014;12(2):177\u2013e13. https:\/\/doi.org\/10.1016\/j.cgh.2013.05.028.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"5240_CR5","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s11695-017-2915-z","volume":"28","author":"RM Cerqueira","year":"2018","unstructured":"Cerqueira RM, Correia M, Vilar H, Manso MC. Cumulative Helicobacter Pylori Eradication Rates by Adopting First- and Second- Line Regimens Proposed by the Maastricht IV Consensus in Obese Patients Undergoing Gastric Bypass Surgery. Obes Surg. 2018;28(3):743\u20137. https:\/\/doi.org\/10.1007\/s11695-017-2915-z.","journal-title":"Obes Surg"},{"key":"5240_CR6","doi-asserted-by":"publisher","unstructured":"Almeida N, Donato MM, Rom\u00e3ozinho JM et al. Beyond Maastricht IV: are standard empiric triple therapies for Helicobacter pylori still useful in a South-European country? BMC Gastroenterol. 2015;15:23. Published 2015 Feb 15. https:\/\/doi.org\/10.1186\/s12876-015-0245-y.","DOI":"10.1186\/s12876-015-0245-y"},{"issue":"5","key":"5240_CR7","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1007\/s10620-017-4536-8","volume":"62","author":"Y Hu","year":"2017","unstructured":"Hu Y, et al. Primary Antibiotic Resistance of Helicobacter pylori in China. Dig Dis Sci vol. 2017;62(5):1146\u201354. https:\/\/doi.org\/10.1007\/s10620-017-4536-8.","journal-title":"Dig Dis Sci vol"},{"issue":"10","key":"5240_CR8","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/S2468-1253(17)30219-4","volume":"2","author":"YT Kuo","year":"2017","unstructured":"Kuo YT, Liou JM, El-Omar EM, et al. Primary antibiotic resistance in Helicobacter pylori in the Asia-Pacific region: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2017;2(10):707\u201315. https:\/\/doi.org\/10.1016\/S2468-1253(17)30219-4.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"5240_CR9","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s12866-019-1517-4","volume":"19","author":"D Wang","year":"2019","unstructured":"Wang D, Guo Q, Yuan Y, Gong Y. The antibiotic resistance of Helicobacter pylori to five antibiotics and influencing factors in an area of China with a high risk of gastric cancer. BMC Microbiol. 2019;19(1):152. https:\/\/doi.org\/10.1186\/s12866-019-1517-4. Published 2019 Jul 4.","journal-title":"BMC Microbiol"},{"issue":"7","key":"5240_CR10","doi-asserted-by":"publisher","first-page":"780e","DOI":"10.1016\/j.cmi.2017.11.010","volume":"24","author":"DS Liu","year":"2018","unstructured":"Liu DS, Wang YH, Zeng ZR, et al. Primary antibiotic resistance of Helicobacter pylori in Chinese patients: a multiregion prospective 7-year study. Clin Microbiol Infect. 2018;24(7):780e. 5-780.e8.","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"5240_CR11","doi-asserted-by":"publisher","first-page":"e12804","DOI":"10.1111\/hel.12804","volume":"26","author":"SY Li","year":"2021","unstructured":"Li SY, Li J, Dong XH, et al. The effect of previous eradication failure on antibiotic resistance of Helicobacter pylori: A retrospective study over 8 years in Beijing. Helicobacter. 2021;26(4):e12804. https:\/\/doi.org\/10.1111\/hel.12804.","journal-title":"Helicobacter"},{"issue":"10","key":"5240_CR12","first-page":"5027","volume":"11","author":"Z Zhong","year":"2021","unstructured":"Zhong Z, Zhang Z, Wang J, et al. A retrospective study of the antibiotic-resistant phenotypes and genotypes of Helicobacter pylori strains in China. Am J Cancer Res. 2021;11(10):5027\u201337. Published 2021 Oct 15.","journal-title":"Am J Cancer Res"},{"issue":"9","key":"5240_CR13","first-page":"6647","volume":"14","author":"Y Zhou","year":"2022","unstructured":"Zhou Y, Deng Y, You Y, et al. Prevalence and risk factors of Helicobacter pylori infection in Ningxia, China: comparison of two cross-sectional studies from 2017 and 2022. Am J Transl Res. 2022;14(9):6647\u201358. Published 2022 Sep.","journal-title":"Am J Transl Res"},{"issue":"25","key":"5240_CR14","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.3748\/wjg.v25.i25.3183","volume":"25","author":"S Smith","year":"2019","unstructured":"Smith S, Fowora M, Pellicano R. Infections with Helicobacter pylori and challenges encountered in Africa. World J Gastroenterol. 2019;25(25):3183\u201395. https:\/\/doi.org\/10.3748\/wjg.v25.i25.3183.","journal-title":"World J Gastroenterol"},{"issue":"3","key":"5240_CR15","doi-asserted-by":"publisher","first-page":"e13103","DOI":"10.1111\/hel.13103","volume":"29","author":"Y Yu","year":"2024","unstructured":"Yu Y, Xue J, Lin F, et al. Global Primary Antibiotic Resistance Rate of Helicobacter pylori in Recent 10 years: A Systematic Review and Meta-Analysis. Helicobacter. 2024;29(3):e13103. https:\/\/doi.org\/10.1111\/hel.13103.","journal-title":"Helicobacter"},{"issue":"5","key":"5240_CR16","doi-asserted-by":"publisher","first-page":"682","DOI":"10.2174\/1389201021666200722162613","volume":"22","author":"ZD Jiang","year":"2021","unstructured":"Jiang ZD, He BS, Zhang ZY, Wang SK, Ran D, Wang ZB. Analysis of the Primary and Post-Treatment Antibiotic Resistance of Helicobacter pylori in the Nanjing Area. Curr Pharm Biotechnol. 2021;22(5):682\u20135. https:\/\/doi.org\/10.2174\/1389201021666200722162613.","journal-title":"Curr Pharm Biotechnol"},{"key":"5240_CR17","doi-asserted-by":"publisher","first-page":"1294379","DOI":"10.3389\/fcimb.2023.1294379","volume":"13","author":"W Wei","year":"2023","unstructured":"Wei W, Wang Z, Li C, Jiang Z, Zhang Z, Wang S. Antibiotic resistance of Helicobacter pylori in Nanjing, China: a cross-section study from 2018 to 2023. Front Cell Infect Microbiol. 2023;13:1294379. https:\/\/doi.org\/10.3389\/fcimb.2023.1294379. Published 2023 Nov 28.","journal-title":"Front Cell Infect Microbiol"},{"key":"5240_CR18","doi-asserted-by":"publisher","unstructured":"Lee JY, Kim N, Nam RH. In Choi S, Lee JW, Lee DH. Primary and secondary antibiotic resistance of Helicobacter pylori in Korea from 2003 to 2018. Helicobacter. 2019;24(6):e12660. https:\/\/doi.org\/10.1111\/hel.12660.","DOI":"10.1111\/hel.12660"},{"key":"5240_CR19","doi-asserted-by":"publisher","first-page":"5519","DOI":"10.2147\/IDR.S383444","volume":"15","author":"H Xu","year":"2022","unstructured":"Xu H, Yun J, Li R, et al. Antibiotics Resistance Prevalence of Helicobacter pylor Strains in Northwest China. Infect Drug Resist. 2022;15:5519\u201328. https:\/\/doi.org\/10.2147\/IDR.S383444. Published 2022 Sep 20.","journal-title":"Infect Drug Resist"},{"issue":"4","key":"5240_CR20","doi-asserted-by":"publisher","first-page":"646","DOI":"10.14309\/ajg.0000000000002600","volume":"119","author":"L Bujanda","year":"2024","unstructured":"Bujanda L, Nyssen OP, Ramos J, et al. Effectiveness of Helicobacter pylori Treatments According to Antibiotic Resistance. Am J Gastroenterol. 2024;119(4):646\u201354. https:\/\/doi.org\/10.14309\/ajg.0000000000002600.","journal-title":"Am J Gastroenterol"},{"key":"5240_CR21","doi-asserted-by":"publisher","unstructured":"Kocsm\u00e1r \u00c9, Buz\u00e1s GM, Szirtes I et al. Primary and secondary clarithromycin resistance in Helicobacter pylori and mathematical modeling of the role of macrolides. Nat Commun. 2021;12(1):2255. Published 2021 Apr 15. https:\/\/doi.org\/10.1038\/s41467-021-22557-7.","DOI":"10.1038\/s41467-021-22557-7"},{"issue":"4","key":"5240_CR22","doi-asserted-by":"publisher","first-page":"2694","DOI":"10.1111\/jam.15396","volume":"132","author":"J Zurita","year":"2022","unstructured":"Zurita J, Sevillano G, Paz Y, Mi\u00f1o A, et al. Mutations associated with Helicobacter pylori antimicrobial resistance in the Ecuadorian population. J Appl Microbiol. 2022;132(4):2694\u2013704. https:\/\/doi.org\/10.1111\/jam.15396.","journal-title":"J Appl Microbiol"},{"key":"5240_CR23","doi-asserted-by":"publisher","first-page":"1510376","DOI":"10.3389\/fmed.2024.1510376","volume":"11","author":"X Su","year":"2025","unstructured":"Su X, Deng Y, Chen X, et al. Effect of an individualized bismuth quadruple regimen guided by 10-day or 14-day antibiotic susceptibility testing for first-line eradication treatment of Helicobacter pylori in Ningxia, China. Front Med (Lausanne). 2025;11:1510376. https:\/\/doi.org\/10.3389\/fmed.2024.1510376. Published 2025 Jan 10.","journal-title":"Front Med (Lausanne)"},{"issue":"1","key":"5240_CR24","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1097\/MOG.0000000000000497","volume":"35","author":"SM Smith","year":"2019","unstructured":"Smith SM, O\u2019Morain C, McNamara D. Helicobacter pylori resistance to current therapies. Curr Opin Gastroenterol. 2019;35(1):6\u201313. https:\/\/doi.org\/10.1097\/MOG.0000000000000497.","journal-title":"Curr Opin Gastroenterol"},{"issue":"10","key":"5240_CR25","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1111\/j.1365-2036.2012.05083.x","volume":"35","author":"CA McNulty","year":"2012","unstructured":"McNulty CA, Lasseter G, Shaw I, et al. Is Helicobacter pylori antibiotic resistance surveillance needed and how can it be delivered? Aliment Pharmacol Ther. 2012;35(10):1221\u201330. https:\/\/doi.org\/10.1111\/j.1365-2036.2012.05083.x.","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"5240_CR26","doi-asserted-by":"publisher","first-page":"900","DOI":"10.14309\/ajg.0000000000000223","volume":"114","author":"D Boltin","year":"2019","unstructured":"Boltin D, Levi Z, Gingold-Belfer R, et al. Impact of Previous Exposure to Macrolide Antibiotics on Helicobacter pylori Infection Treatment Outcomes. Am J Gastroenterol. 2019;114(6):900\u20136. https:\/\/doi.org\/10.14309\/ajg.0000000000000223.","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"5240_CR27","doi-asserted-by":"publisher","first-page":"e13091","DOI":"10.1111\/hel.13091","volume":"29","author":"J Xie","year":"2024","unstructured":"Xie J, Peng J, Liu D, et al. Treatment failure is a key factor in the development of Helicobacter pylori resistance. Helicobacter. 2024;29(3):e13091. https:\/\/doi.org\/10.1111\/hel.13091.","journal-title":"Helicobacter"},{"key":"5240_CR28","doi-asserted-by":"publisher","first-page":"4596","DOI":"10.3748\/wjg.v24.i40.4596","volume":"24","author":"YW Zhang","year":"2018","unstructured":"Zhang YW, Hu WL, Cai Y, Zheng WF, Du Q, Kim JJ, et al. Outcomes of furazolidone- and amoxicillin-based quadruple therapy for Helicobacter pylori infection and predictors of failed eradication. World J Gastroenterol. 2018;24:4596\u2013605.","journal-title":"World J Gastroenterol"},{"key":"5240_CR29","doi-asserted-by":"publisher","first-page":"e12468","DOI":"10.1111\/hel.12468","volume":"23","author":"L Zhuge","year":"2018","unstructured":"Zhuge L, Wang Y, Wu S, Zhao R-L, Li Z, Xie Y. Furazolidone treatment for Helicobacter Pylori infection: A systematic review and meta-analysis. Helicobacter. 2018;23:e12468.","journal-title":"Helicobacter"},{"key":"5240_CR30","doi-asserted-by":"publisher","first-page":"771876","DOI":"10.3389\/fphar.2022.771876","volume":"13","author":"M Niu","year":"2022","unstructured":"Niu M, Zhou Y, Xie Y, Li X, Tian Y, Yao L, et al. Comparison of the dual therapy of ilaprazole-amoxicillin and the bismuth quadruple therapy of ilaprazole-amoxicillin-furazolidone-bismuthglycyrrhizinate for eradication of Helicobacter pylori. Front Pharmacol. 2022;13:771876.","journal-title":"Front Pharmacol"},{"issue":"39","key":"5240_CR31","doi-asserted-by":"publisher","first-page":"4295","DOI":"10.3748\/wjg.v30.i39.4295","volume":"30","author":"YR Zhao","year":"2024","unstructured":"Zhao YR, Wang XJ, Zhu MJ, et al. Efficacy and safety of low-dose tetracycline, amoxicillin quadruple therapy in Helicobacter pylori infection: A retrospective single center study. World J Gastroenterol. 2024;30(39):4295\u2013304. https:\/\/doi.org\/10.3748\/wjg.v30.i39.4295.","journal-title":"World J Gastroenterol"},{"key":"5240_CR32","doi-asserted-by":"publisher","unstructured":"Zhou B-G, et al. High-dose dual therapy versus bismuth-containing quadruple therapy for Helicobacter pylori eradication: a systematic review and meta-analysis with trial sequential analysis. Therapeutic Adv Gastroenterol vol. Jan. 2023;16 17562848221147756(10). https:\/\/doi.org\/10.1177\/17562848221147756.","DOI":"10.1177\/17562848221147756"},{"issue":"13","key":"5240_CR33","doi-asserted-by":"publisher","first-page":"100863","DOI":"10.3748\/wjg.v31.i13.100863","volume":"31","author":"XE Yang","year":"2025","unstructured":"Yang XE, Zhang SJ, Liu Y, et al. Amoxicillin high-dose dual therapy for Helicobacter pylori primary eradication: Proton pump inhibitor and potassium-competitive acid blocker, which\u2019s better? World J Gastroenterol. 2025;31(13):100863. https:\/\/doi.org\/10.3748\/wjg.v31.i13.100863.","journal-title":"World J Gastroenterol"},{"issue":"4","key":"5240_CR34","doi-asserted-by":"publisher","first-page":"e12970","DOI":"10.1111\/hel.12970","volume":"28","author":"J Hu","year":"2023","unstructured":"Hu J, Mei H, Su NY, et al. Eradication rates of Helicobacter pylori in treatment-naive patients following 14-day vonoprazan-amoxicillin dual therapy: A multicenter randomized controlled trial in China. Helicobacter. 2023;28(4):e12970. https:\/\/doi.org\/10.1111\/hel.12970.","journal-title":"Helicobacter"},{"issue":"5","key":"5240_CR35","doi-asserted-by":"publisher","first-page":"e12918","DOI":"10.1111\/hel.12918","volume":"27","author":"W Gao","year":"2022","unstructured":"Gao W, Teng G, Wang C, Xu Y, Li Y, Cheng H. Eradication rate and safety of a simplified rescue therapy: 14-day vonoprazan and amoxicillin dual regimen as rescue therapy on treatment of Helicobacter pylori infection previously failed in eradication: A real-world, retrospective clinical study in China. Helicobacter. 2022;27(5):e12918. https:\/\/doi.org\/10.1111\/hel.12918.","journal-title":"Helicobacter"},{"issue":"2","key":"5240_CR36","doi-asserted-by":"publisher","first-page":"e12475","DOI":"10.1111\/hel.12475","volume":"23","author":"WZ Liu","year":"2018","unstructured":"Liu WZ, Xie Y, Lu H, et al. Fifth Chinese National Consensus Report on the management of Helicobacter pylori infection. Helicobacter. 2018;23(2):e12475. https:\/\/doi.org\/10.1111\/hel.12475.","journal-title":"Helicobacter"},{"key":"5240_CR37","doi-asserted-by":"publisher","first-page":"998240","DOI":"10.3389\/fmicb.2022.998240","volume":"13","author":"X Xu","year":"2022","unstructured":"Xu X, He C, Zhu Y. Treatment of refractory Helicobacter pylori infection: A new challenge for clinicians. Front Microbiol. 2022;13:998240. https:\/\/doi.org\/10.3389\/fmicb.2022.998240. Published 2022 Oct 18.","journal-title":"Front Microbiol"},{"issue":"1","key":"5240_CR38","doi-asserted-by":"publisher","first-page":"2464938","DOI":"10.1080\/07853890.2025.2464938","volume":"57","author":"J Xie","year":"2025","unstructured":"Xie J, Peng J, Wu S, et al. Efficacy and safety of tetracycline vs. amoxicillin in furazolidone-based rescue therapy for Helicobacter pylori: a real-world analysis. Ann Med. 2025;57(1):2464938. https:\/\/doi.org\/10.1080\/07853890.2025.2464938.","journal-title":"Ann Med"},{"issue":"9","key":"5240_CR39","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.3390\/antibiotics10091028","volume":"10","author":"E Resina","year":"2021","unstructured":"Resina E, Gisbert JP. Rescue Therapy with Furazolidone in Patients with at Least Five Eradication Treatment Failures and Multi-Resistant H. pylori infection. Antibiot (Basel). 2021;10(9):1028. https:\/\/doi.org\/10.3390\/antibiotics10091028. Published 2021 Aug 24.","journal-title":"Antibiot (Basel)"},{"issue":"10","key":"5240_CR40","doi-asserted-by":"publisher","first-page":"e0109025","DOI":"10.1128\/msystems.01090-25","volume":"10","author":"Y Li","year":"2025","unstructured":"Li Y, Xu X, Peng C, et al. Comprehensive characterization of gastrointestinal microbiota dysbiosis in patients with refractory Helicobacter pylori infection. mSystems. 2025;10(10):e0109025. https:\/\/doi.org\/10.1128\/msystems.01090-25.","journal-title":"mSystems"},{"issue":"6","key":"5240_CR41","doi-asserted-by":"publisher","first-page":"107600","DOI":"10.1016\/j.ijantimicag.2025.107600","volume":"66","author":"YH Liu","year":"2025","unstructured":"Liu YH, Zhang J, Li DH, et al. The impact of probiotics on Helicobacter pylori eradication with bismuth quadruple therapy: A systematic review and meta-analysis. Int J Antimicrob Agents. 2025;66(6):107600. https:\/\/doi.org\/10.1016\/j.ijantimicag.2025.107600.","journal-title":"Int J Antimicrob Agents"},{"issue":"2","key":"5240_CR42","doi-asserted-by":"publisher","first-page":"78","DOI":"10.4103\/sjg.SJG_589_19","volume":"26","author":"A Liu","year":"2020","unstructured":"Liu A, Wang Y, Song Y, Du Y. Treatment with compound Lactobacillus acidophilus followed by a tetracycline- and furazolidone-containing quadruple regimen as a rescue therapy for Helicobacter pylori infection. Saudi J Gastroenterol. 2020;26(2):78\u201383. https:\/\/doi.org\/10.4103\/sjg.SJG_589_19.","journal-title":"Saudi J Gastroenterol"},{"issue":"4","key":"5240_CR43","doi-asserted-by":"publisher","first-page":"e70056","DOI":"10.1111\/hel.70056","volume":"30","author":"TL Yan","year":"2025","unstructured":"Yan TL, Wang JH, Zhu RK, et al. Vonoprazan Improves Efficacy of Bismuth Quadruple Therapy for Helicobacter pylori Rescue Treatment: A Multicenter Randomized Controlled Trial. Helicobacter. 2025;30(4):e70056. https:\/\/doi.org\/10.1111\/hel.70056.","journal-title":"Helicobacter"},{"key":"5240_CR44","doi-asserted-by":"publisher","unstructured":"Sue S, Sato T, Matsubayashi M, Kaneko H, Irie K, Maeda S. Antibiotic Susceptibility-Guided Concomitant Therapy Regimen with Vonoprazan, High-Dose Amoxicillin, Clarithromycin, and Metronidazole for Helicobacter pylori Eradication as Fourth-Line Regimen: An Interventional Study. Microorganisms. 2024;12(10):2104. Published 2024 Oct 21. https:\/\/doi.org\/10.3390\/microorganisms12102104.","DOI":"10.3390\/microorganisms12102104"},{"key":"5240_CR45","doi-asserted-by":"publisher","unstructured":"Fang Y, Jiang S, Zhou X et al. Whole-genome sequencing analyses and antibiotic resistance situation of 48 Helicobacter pylori strains isolated in Zhejiang, China. Gut Pathog. 2024;16(1):62. Published 2024 Oct 23. https:\/\/doi.org\/10.1186\/s13099-024-00656-2.","DOI":"10.1186\/s13099-024-00656-2"},{"issue":"3","key":"5240_CR46","doi-asserted-by":"publisher","first-page":"e12960","DOI":"10.1111\/hel.12960","volume":"28","author":"S Hu","year":"2023","unstructured":"Hu S, Zhou Y, Deng Y, et al. Characteristics of phenotypic antibiotic resistance of Helicobacter pylori and its correlation with genotypic antibiotic resistance: A retrospective study in Ningxia. Helicobacter. 2023;28(3):e12960. https:\/\/doi.org\/10.1111\/hel.12960.","journal-title":"Helicobacter"},{"issue":"1","key":"5240_CR47","doi-asserted-by":"publisher","first-page":"34244","DOI":"10.1038\/s41598-025-16264-2","volume":"15","author":"Z Xue","year":"2025","unstructured":"Xue Z, Zhao Q, Pei F, et al. Helicobacter pylori antimicrobial resistance and gene variants in Shandong Province. Sci Rep. 2025;15(1):34244. https:\/\/doi.org\/10.1038\/s41598-025-16264-2. Published 2025 Oct 1.","journal-title":"Sci Rep"},{"key":"5240_CR48","doi-asserted-by":"publisher","unstructured":"Huang J, Li Z, Ge F et al. Functional determination of site-mutations in rdxA involved in metronidazole resistance of Helicobacter pylori. Front Cell Dev Biol. 2024;12:1435064. Published 2024 Jul 19. https:\/\/doi.org\/10.3389\/fcell.2024.1435064.","DOI":"10.3389\/fcell.2024.1435064"},{"issue":"6","key":"5240_CR49","doi-asserted-by":"publisher","first-page":"e0218821","DOI":"10.1128\/aac.02188-21","volume":"66","author":"Y Zhou","year":"2022","unstructured":"Zhou Y, Zhong Z, Hu S, et al. A Survey of Helicobacter pylori Antibiotic-Resistant Genotypes and Strain Lineages by Whole-Genome Sequencing in China. Antimicrob Agents Chemother. 2022;66(6):e0218821. https:\/\/doi.org\/10.1128\/aac.02188-21.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"5240_CR50","doi-asserted-by":"publisher","first-page":"45439","DOI":"10.1038\/s41598-025-29451-y","volume":"15","author":"W Tao","year":"2025","unstructured":"Tao W, Ma W, Zhao G, et al. Characterization of antibiotic resistance and biofilm formation in clinical Helicobacter pylori isolates from Ningxia, China. Sci Rep. 2025;15(1):45439. https:\/\/doi.org\/10.1038\/s41598-025-29451-y. Published 2025 Nov 27.","journal-title":"Sci Rep"}],"container-title":["BMC Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12866-026-05240-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12866-026-05240-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12866-026-05240-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:35:57Z","timestamp":1787020557000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12866-026-05240-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5240"],"URL":"https:\/\/doi.org\/10.1186\/s12866-026-05240-z","relation":{},"ISSN":["1471-2180"],"issn-type":[{"value":"1471-2180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]},"assertion":[{"value":"26 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All participants signed an informed consent form before participating in the study. The study protocol was approved by the Ethics Committee of Ningxia Hui Autonomous Region People\u2019s Hospital (2021SLCJ2486) and accordance with the Declaration of Helsinki.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"737"}}